CytomX Therapeutics (CTMX) Assets Average (2015 - 2026)

CytomX Therapeutics has reported Assets Average for 12 years, with the latest figure at $255.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 133.27% year-over-year to $255.5 million; the trailing twelve-month figure through Mar 2026 stood at $255.5 million (up 133.27% YoY), and the FY2025 full-year result was $136.0 million, down 15.58% from the prior year.
• Assets Average for Q1 2026 stood at $255.5 million, up from $154.9 million in the prior quarter.
• The five-year high for Assets Average was $318.1 million in Q1 2022, with the low at $109.5 million in Q1 2025.
• Historically, Assets Average has averaged $202.8 million across 5 years, with a median of $211.5 million in 2023.
• Annual changes were most pronounced in 2025 — Assets Average sank 43.33% — and 2026, when it surged 133.27%.
• CytomX Therapeutics' Assets Average stood at $243.7 million in 2022, then retreated by 13.22% to $211.5 million in 2023, then tumbled by 38.64% to $129.8 million in 2024, then climbed by 19.38% to $154.9 million in 2025, then jumped by 64.91% to $255.5 million in 2026.
• The last three Assets Average figures came in at $255.5 million (Q1 2026), $154.9 million (Q4 2025), and $166.7 million (Q3 2025), per Business Quant data.